Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SB-435495

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsPyrimidinones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis.
The present study aimed to investigate the effects of lipoprotein-associated phospholipase A2 (Lp-PLA2) on endothelial… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
2016
2016
Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes
Significance Breakdown of the blood–retinal barrier (BRB) is central to diabetic macular edema (DME). Here, we demonstrate that… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
The Role of Lipoprotein-Associated Phospholipase A₂ in a Murine Model of Experimental Autoimmune Uveoretinitis
Macrophage activation is, in part, regulated via hydrolysis of oxidised low density lipoproteins by Lipoprotein-Associated… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic ‘eat-me’ signals: cleavage and inhibition of phagocytosis by Lp-PLA2
Diversified anionic phospholipids, phosphatidylserines (PS), externalized to the surface of apoptotic cells are universal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in aspergillus fumigatus sensitized mice
BackgroundLipoprotein-associated phospholipase A2 (Lp-PLA2)/platelet-activating factor acetylhydrolase (PAF-AH) has been… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Modification of the pyrimidone 5-substituent in clinical candidate SB-435495 has given a series of inhibitors of recombinant… Expand
Is this relevant?
2003
2003
The Discovery of SB-435495: A Potent, Orally Active Inhibitor of Lipoprotein-Associated Phospholipase A2 for Evaluation in Man.
A significant problem in cancer treatment is the development of tumor resistance to chemotherapeutic agents. Acquired drug… Expand
  • figure 1
Is this relevant?
2002
2002
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
The introduction of a functionalised amido substituent into a series of 1-(biphenylmethylacetamido)-pyrimidones has given a… Expand
Is this relevant?
2001
2001
Lp-PLA2 inhibitors (GlaxoSmithKline).
  • M. Booker
  • IDrugs : the investigational drugs journal
  • 2001
    • Corpus ID: 40339235
GlaxoSmithKline is investigating a series of substituted pyrimidin-4-ones, including SB-435495, as reversible inhibitors of… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE